Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.59 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460580 | 0.92 | PLA2G2A (0.56) | LTB4RLTB4R2PLA2G2ACHRM1POLB | |
| SCHEMBL6250269 | 0.85 | PLA2G2A (0.48) | LTB4RLTB4R2PLA2G2ACHRM1POLB | |
| SCHEMBL6246636 | 0.84 | PLA2G2A (0.47) | LTB4RLTB4R2PLA2G2ACHRM1POLB | |
| SCHEMBL5466916 | 0.82 | PDE4A (0.52) | LTB4RLTB4R2PLA2G2APOLBMAPT | |
| SCHEMBL30497877 | 0.76 | POLB (0.78) | CHRM1POLBTP53MAPTSMN1; SMN2 | |
| SCHEMBL3232279 | 0.76 | CHRM1 (0.82) | CHRM1POLBTP53MAPTSMN1; SMN2 | |
| SCHEMBL6247594 | 0.76 | LTB4R (0.41) | LTB4RLTB4R2PLA2G2APOLBTP53 | |
| SCHEMBL14785275 | 0.75 | PTGER1 (0.42) | LTB4RLTB4R2PLA2G2AMAPTLMNA | |
| SCHEMBL2000264 | 0.75 | LMNA (0.59) | PLA2G2ACHRM1MAPTALDH1A1HTT | |
| SCHEMBL9023322 | 0.75 | LTB4R (1.00) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093531-A1 | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | ELBION AG | 2007-04-26 | — | — | US | disclosed |
| US-7166637-B2 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | ELBION AG (DE) | 2007-01-23 | — | — | US | disclosed |
| CN-1711082-A | Novel hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | ELBION AG (DE) | 2005-12-21 | — | — | CN | disclosed |
| EP-1562584-A1 | NOVEL HYDROXYINDOLES, USE AS INHIBITORS OF PHOSPHODIESTERASE 4 AND METHOD FOR PRODUCTION THEREOF | Elbion AG (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147759-A1 | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | ELBION AG (DE) | 2004-07-29 | — | — | US | disclosed |
| WO-2004045607-A1 | NOVEL HYDROXYINDOLES, USE AS INHIBITORS OF PHOSPHODIESTERASE 4 AND METHOD FOR PRODUCTION THEREOF | ELBION AG (DE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147759-A1 | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | PDE4B, PDE4A, PDE4D | LTB4R 224/4885LTB4R2 150/4885PLA2G2A 1184/4885 |
| US-20070093531-A1 | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | PDE4B, PDE4A, PDE4D | LTB4R 175/4885LTB4R2 146/4885PLA2G2A 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.